logo-loader
viewTissue Regenix Group PLC

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue.

The group, which already has experience of commercialising products in the US, is planning a commercial launch in the second half of 2016.

SurgiPure XD will treat the most complex types of hernias, a market worth in itself US$300 mln.

He says Tissue Regenix is "a busy little company" that is "advancing on many fronts."

Quick facts: Tissue Regenix Group PLC

Price: 1.1 GBX

AIM:TRX
Market: AIM
Market Cap: £12.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix to expand sales force after latest US DermaPure approvals

Antony Odell, the chief executive of Tissue Regenix (LON:TRX) says he will expand the firm’s sales division after its Derma Pure skin graft gained approval for coverage in over half of the American states. Noridian Healthcare Solutions and Palmetto GBA’s green light means DermaPure is now...

on 06/26/2015

RNS

Price Monitoring Extension

2 weeks, 1 day ago

Directorate Change

2 weeks, 4 days ago

Holding(s) in Company

3 weeks, 1 day ago

Holding(s) in Company

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 2 days ago

Second Price Monitoring Extn

3 weeks, 4 days ago

Price Monitoring Extension

3 weeks, 4 days ago

2 min read